BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024. “We're pleased to welcome Bryan to our Board,” said Michael Goldberg, CareDx Board Chairperson. “His financial expertise ...

CareDx, Inc. (NASDAQ:CDNA) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Gregory Chodaczek - Managing Director of Investor Relations Alexander Johnson - President of Patient and Testing Services Abhishek Jain - CFO Michael Goldberg - Chairman Robert Woodward - Chief Scientific Officer Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Yi Chen - H.C. Wainwright Operator Greetings, and welcome to CareDx, Inc. Fourth Quarter 2023 Earnings C ...

Stock-based Compensation We use the Black-Scholes Model, which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. We estimate the expected option lives using historical data, estimate volatility using our own historical stock prices, estimate risk-free rates using the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and estimate dividend yield using our exp ...

Wall Street analysts forecast that CareDx (CDNA) will report quarterly loss of $0.24 per share in its upcoming release, pointing to a year-over-year decline of 242.9%. It is anticipated that revenues will amount to $65.1 million, exhibiting a decline of 21% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings, Transplantati ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA). CareDx was found to have not infringed on Natera patent 10,655,180 (the ‘180 patent) and found to have infringed on Natera patent 11,111,544 (the ‘544 patent). ...

CareDx, Inc (NASDAQ:CDNA) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and Testing Services Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Michael Goldberg - Chairperson of the Board Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Jacob Krahenbuhl - Stephens Dipesh Patel - H.C. Weinright Operator Goo ...

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regu ...

CareDx, Inc. (NASDAQ:CDNA) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, IR Reg Seeto - President, CEO Abhishek Jain - CFO Robert Woodward - SVP, R&D Conference Call Participants Andrew Cooper - Raymond James Brandon Couillard - Jefferies Alex Nowak - Craig-Hallum Capital Mason Carrico - Stephens Inc. Operator Greetings, and welcome to the CareDx, Incorporated Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a remind ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36536 __ ...